Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Hilde H. Nienhuis"'
Autor:
Si-Qi Qiu, Johan van Rooijen, Hilde H. Nienhuis, Bert van der Vegt, Hetty Timmer-Bosscha, Elise van Leeuwen-Stok, Annemiek M. E. Walenkamp, Carolien H. M. van Deurzen, Geertruida H. de Bock, Elisabeth G. E. de Vries, Carolien P. Schröder
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-10 (2020)
Abstract Background Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight may improve male breast
Externí odkaz:
https://doaj.org/article/6dac41f9d188433fb23a4a389a57ad75
Autor:
Clasina M Venema, Michel van Kruchten, Hilde H. Nienhuis, Rudolf S N Fehrmann, Rulla M. Tamimi, Si-Qi Qiu, Elisabeth G.E. de Vries, Tessa G Steenbruggen, Rico D. Bense, Geke A. P. Hospers, Carolina P. Schröder, Myles Brown
Publikováno v:
Pharmacology & Therapeutics. 200:135-147
The androgen receptor (AR) is a drug target in breast cancer, and AR-targeted therapies have induced tumor responses in breast cancer patients. In this review, we summarized the role of AR in breast cancer based on preclinical and clinical data. Resp
Autor:
Bert van der Vegt, Carolien H.M. van Deurzen, Elisabeth G.E. de Vries, Carolien P. Schröder, Elise van Leeuwen-Stok, Hilde H. Nienhuis, Geertruida H. de Bock, Annemiek M E Walenkamp, Si-Qi Qiu, Johan M. van Rooijen, Hetty Timmer-Bosscha
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-10 (2020)
Breast cancer research, 22(1):30. BioMed Central Ltd.
Breast Cancer Research : BCR
Breast cancer research : BCR, 22. BioMed Central Ltd.
Breast cancer research, 22(1):30. BioMed Central Ltd.
Breast Cancer Research : BCR
Breast cancer research : BCR, 22. BioMed Central Ltd.
Background Breast cancer is rare in men, but management is focused on tumor characteristics commonly found in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight may improve male breast cancer m
Autor:
Carolien P. Schröder, Elisabeth G.E. de Vries, Alfons H. H. Bongaerts, Erik F. J. de Vries, Michel van Kruchten, Andor W. J. M. Glaudemans, Hilde H. Nienhuis, Sjoerd G. Elias, Geke A. P. Hospers
Publikováno v:
Journal of Nuclear Medicine, 59(8), 1212. Society of Nuclear Medicine Inc.
Journal of Nuclear Medicine, 59(8), 1212-1218. SOC NUCLEAR MEDICINE INC
Journal of Nuclear Medicine, 59(8), 1212-1218. SOC NUCLEAR MEDICINE INC
Heterogeneity of estrogen receptor (ER) expression in breast cancer is recognized. However, knowledge about varying expression across metastases and surrounding normal tissue in patients is scarce. We therefore analyzed 16 alpha-F-18-fluoro-17 beta-e
Autor:
Elisabeth G.E. de Vries, Hilde H. Nienhuis, Marlous Arjaans, Carolina P. Schröder, Hetty Timmer-Bosscha
Publikováno v:
Oncotarget, 6(27), 24436-24447. Impact Journals LLC
Oncotarget
Oncotarget
// Hilde H. Nienhuis 1,* , Marlous Arjaans 1,* , Hetty Timmer-Bosscha 1 , Elisabeth G.E. de Vries 1 and Carolina P. Schroder 1 1 Department of Medical Oncology, University of Groningen and University Medical, Center Groningen, Groningen, The Netherla
Autor:
Michael Reiss, Hilde H. Nienhuis, Whitney Banach-Petrosky, Vidya Ganapathy, Gregory D. Miles, Aparna Kareddula, Wen Xie
Publikováno v:
Clinical & Experimental Metastasis, 29(5), 493-509. SPRINGER
Luminal breast cancer is the most frequently encountered type of human breast cancer and accounts for half of all breast cancer deaths due to metastatic disease. We have developed new in vivo models of disseminated human luminal breast cancer that cl
Autor:
B. van der Vegt, Carolien P. Schröder, E.G.E. de Vries, Beth Overmoyer, Hilde H. Nienhuis, Mathilde Jalving, M. N. Lub-de Hooge, Adrienne H. Brouwers, Hetty Timmer-Bosscha, Sietske B. M. Gaykema
Publikováno v:
Pharmacologytherapeutics. 147
It is increasingly evident that not only breast cancer cells, but also the tissue embedding these cells: the tumor microenvironment, plays an important role in tumor progression, metastasis formation and treatment sensitivity. This review focuses on
Autor:
Jos G. W. Kosterink, Anton G.T. Terwisscha van Scheltinga, Elisabeth G.E. de Vries, Hilde H. Nienhuis, Marjolijn N. Lub-de Hooge, Linda Pot, Hetty Timmer-Bosscha, Sietske B. M. Gaykema, Carolien P. Schröder, Paul Berghuis
Publikováno v:
European Journal of Cancer, 50(14), 2508-2516. ELSEVIER SCI LTD
European Journal of Cancer
European Journal of Cancer
Purpose: Triple negative breast cancer (TNBC) is biologically characterised by heterogeneous presence of molecular pathways underlying it. Insulin-like growth factor receptor-1 (IGF-1R) expression and vascular endothelial growth factor-A (VEGF-A) hav
Autor:
Erik F. J. de Vries, Elisabeth G.E. de Vries, Michel van Kruchten, Hilde H. Nienhuis, Geke A. P. Hospers, Alfons H. H. Bongaerts, Carolina P. Schröder, Andor W. J. M. Glaudemans
Publikováno v:
Journal of Clinical Oncology, 33(15). AMER SOC CLINICAL ONCOLOGY
527 Background: Recent data suggests that differences in locations of metastases could have implications for tumor characteristics and thus for therapy response. Limited knowledge is available in t...
Autor:
Hilde H. Nienhuis, Hetty Timmer-Bosscha, Marlous Arjaans, Carolina P. Schröder, Elisabeth G.E. de Vries
Publikováno v:
Cancer Research. 73:4950-4950
Introduction - Targeting breast cancer (BC) via its microenvironment is a way to avoid tumor plasticity and development of resistance towards therapy. Bisphosphonates (BPs) are used to treat BC bone metastases. Prior studies suggest that BPs also exe